Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.
read full article ›Post-FOURIER: what Amgen needs to do to improve Repatha reimbursement.
read full article ›President Donald Trump says drug prices are astronomical and something needs to be done. Pharmaceutical giants have an answer that doesn’t involve lowering list prices: refunding some of the money to insurers if a drug doesn’t work as expected.
read full article ›When it comes to medicines, value is often in the eye of the beholder. A new analysis finds that what multiple sclerosis patients value in their medicines is generally overlooked by payers and doctors. As a result, drug companies subsequently disregard what matters most to patients, according to Real Endpoints, a research firm that conducted the analysis.
read full article ›Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.
read full article ›Promising Approaches to Treating Cancer Stalked by Cost Constraints.
read full article ›Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.
read full article ›New cardiovascular outcomes trial data from Amgen Inc. (NASDAQ: AMGN) PCSK9 inhibitor Repatha evolocumab disappointed investors, but payers are still evaluating the data and Amgen's proposed outcome-based pricing model, which could alleviate their risk.
read full article ›FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.
read full article ›